BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim JT, Napier DL, Kim J, Li C, Lee EY, Weiss HL, Wang Q, Evers BM. Ketogenesis alleviates TNFα-induced apoptosis and inflammatory responses in intestinal cells. Free Radic Biol Med 2021;172:90-100. [PMID: 34087430 DOI: 10.1016/j.freeradbiomed.2021.05.032] [Reference Citation Analysis]
2 Okoro EU. TNFα-Induced LDL Cholesterol Accumulation Involve Elevated LDLR Cell Surface Levels and SR-B1 Downregulation in Human Arterial Endothelial Cells. Int J Mol Sci 2021;22:6236. [PMID: 34207810 DOI: 10.3390/ijms22126236] [Reference Citation Analysis]
3 Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines 2021;9:1511. [PMID: 34829740 DOI: 10.3390/biomedicines9111511] [Reference Citation Analysis]
4 Poppelaars F, Gaya da Costa M, Faria B, Eskandari SK, Seelen MA, Damman J. Tumor Necrosis Factor-α Gene Polymorphism is Associated with Short- and Long-Term Kidney Allograft Outcomes. JIR 2022;Volume 15:2243-54. [DOI: 10.2147/jir.s334738] [Reference Citation Analysis]
5 Makalish TP, Golovkin IO, Oberemok VV, Laikova KV, Temirova ZZ, Serdyukova OA, Novikov IA, Rosovskyi RA, Gordienko AI, Zyablitskaya EY, Gafarova EA, Yurchenko KA, Fomochkina II, Kubyshkin AV. Anti-Rheumatic Effect of Antisense Oligonucleotide Cytos-11 Targeting TNF-α Expression. Int J Mol Sci 2021;22:1022. [PMID: 33498456 DOI: 10.3390/ijms22031022] [Reference Citation Analysis]
6 Roberts KJ, Cubitt MF, Carlton TM, Rodrigues-Duarte L, Maggiore L, Chai R, Clare S, Harcourt K, MacDonald TT, Ray KP, Vossenkämper A, West MR, Crowe JS. Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. Sci Rep 2021;11:19422. [PMID: 34593832 DOI: 10.1038/s41598-021-97236-0] [Reference Citation Analysis]
7 Mecocci S, Ottaviani A, Razzuoli E, Fiorani P, Pietrucci D, De Ciucis CG, Dei Giudici S, Franzoni G, Chillemi G, Cappelli K. Cow Milk Extracellular Vesicle Effects on an In Vitro Model of Intestinal Inflammation. Biomedicines 2022;10:570. [DOI: 10.3390/biomedicines10030570] [Reference Citation Analysis]
8 Felice C, Lewis A, Iqbal S, Gordon H, Rigoni A, Colombo MP, Armuzzi A, Feakins R, Lindsay JO, Silver A. Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients. Cell Mol Gastroenterol Hepatol 2021;11:889-891.e6. [PMID: 33232823 DOI: 10.1016/j.jcmgh.2020.11.009] [Reference Citation Analysis]
9 Moreno LO, Fernández-tomé S, Abalo R. Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. Biologics 2021;1:189-210. [DOI: 10.3390/biologics1020012] [Reference Citation Analysis]
10 Lauro R, Mannino F, Irrera N, Squadrito F, Altavilla D, Squadrito G, Pallio G, Bitto A. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review. Biomedicines 2021;9:1748. [PMID: 34944563 DOI: 10.3390/biomedicines9121748] [Reference Citation Analysis]
11 Eder P, Zielińska A, Karczewski J, Dobrowolska A, Słomski R, Souto EB. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions. J Nanobiotechnology 2021;19:346. [PMID: 34715852 DOI: 10.1186/s12951-021-01090-1] [Reference Citation Analysis]
12 Bassotti G, Fruganti A, Maconi G, Marconi P, Fettucciari K. Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease May be Favoured by the Effects of Proinflammatory Cytokines on the Enteroglial Network. J Inflamm Res 2021;14:7443-53. [PMID: 35002278 DOI: 10.2147/JIR.S328628] [Reference Citation Analysis]
13 Faber S, Lahoti T, Taylor E, Lewis L, Sapiro J, Toledo Sales V, Dragan Y, Jeffy B. Current Therapeutic Landscape and Safety Roadmap for Targeting the Aryl Hydrocarbon Receptor in Inflammatory Gastrointestinal Indications. Cells 2022;11:1708. [DOI: 10.3390/cells11101708] [Reference Citation Analysis]